Skip to main content
All lobbying filings

THORN RUN PARTNERS

Lobbying for THE BIOSIMILARS FORUM · Non-profit Organization

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$100,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 2
  • STUART CHAPMAN
    Previously held: Chief of Staff, Representative Carolyn McCarthy; Chief of Staff, Representative Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary, Representative Barbara Lee
  • ALEX DELPIZZO
    Previously held: Legislative Director/Legislative Asst, Rep. Ferguson; Staff Asst, House Transportation and Infrastructure Committee

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.

Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.

 Bills named in this filing 5
  • H.R. 5526
    Biosimilar Red Tape Elimination Act
  • S. 1954
    Biosimilar Red Tape Elimination Act
  • H.R. 9661
    Expedited Access to Biosimilars Act
  • S. 1414
    Expedited Access to Biosimilars Act
  • S. 2256
    Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem